CONFEROPORT 0.5 mg, extended-release capsule 30 capsules
Active ingredients: Tacrolimus, Tacrolimus hydrate
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CONFEROPORT 0,5 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) PVC PVDC aluminium suremballée(s)/surpochée(s) de 1 gélule(s)
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Sept 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69458135CIP73022378CIP133400930223789Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TACROLIMUSgélule | 0,5 mg · une gélule | FT |
| TACROLIMUS MONOHYDRATÉgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.